Kaitlyn Bader, Assistant Managing Editor

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

Share with us the topics you want to learn more about at Fall Clinical.

Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.

Christophe Bourdon, CEO, discusses LEO Pharma's groundbreaking presentations at EADV, delgocitinib's US pending approval, and the company's commitment to addressing chronic hand eczema.

In case you missed it, this week we had news about delgocitinib's launch in Germany, the FDA clearance of Accure's laser system for long-term acne treatment, BE BOLD study highlights, and more.

An 82-year-old woman with PPP and treated with roflumilast cream 0.3% achieved complete clearance after 5 weeks of treatment.

Omar Noor, MD, FAAD, hosted a live Case-Based Roundtable discussion with local dermatology clinicians to discuss 2 patients with plaque psoriasis and what would be the ideal topical treatment for each.

Renata Block, PA-C, and Karan Lal, DO, discuss the critical role of advanced practice providers in dermatology, the power of mentorship, and how collaborative learning improves patient outcomes.

In case you missed it, we had news about benzene in benzoyl peroxide acne products tested at room temperature, the FDA's approved sNDA for 3 tubes of aminolevulinic acid hydrochloride, phase 2b trial data of zasocitinib, and more.

Christopher Bunick, MD, PhD, reviews the latest findings on benzene in benzoyl peroxide, highlighting the importance of proper storage and patient safety.

This week’s collection of the latest dermatologic studies includes the potential association between hidradenitis suppurativa and infertility, refractory pediatric atopic dermatitis treated with dupilumab and abrocitinib, and omalizumab's efficacy in chronic inducible urticaria.

New peer-reviewed research published in the Journal of Investigative Dermatology examined 111 products at room temperature.

In case you missed it, this week we had news about bimekizumab's 2-year efficacy data in hidradenitis suppurativa, new long-term results for ESK-001 in psoriasis, late-breaking 40-week efficacy and safety data for povorcitinib for prurigo nodularis, and more.

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

Learn more about the in-depth topics covered in the September 2024 print issue of Dermatology Times.

Shawn Kwatra, MD, presented the Incyte data at EADV 2024.

Gil Yosipovitch, MD, reviews differences including lesion appearance, cytokine pathways, treatment options, and more.

In case you missed it, this week we had news about bimekizumab's FDA approval for psoriatic arthritis, the acceptance of roflumilast foam's sNDA for scalp and body psoriasis, exclusive interviews from EADV 2024, and more.

Arash Mostaghimi, MD, MPH, MPA, provides insights into what clinicians need to know about deuruxolitinib for severe AA.

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

As conference season approaches the last few months of the year, catch up on highlights from NP & PA conferences, including Fall Clinical for PAs and NPs and SDPA Summer.

Catch up on eczema advancements throughout the year, including news on contact dermatitis, chronic hand eczema, and more.